{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:07:20Z","timestamp":1760148440388,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The detection of ROS1 rearrangements in metastatic non-squamous non-small cell lung carcinoma (NS-NSCLC) permits administration of efficient targeted therapy. Detection is based on a testing algorithm associated with ROS1 immunohistochemistry (IHC) screening followed by ROS1 FISH and\/or next generation sequencing (NGS) to confirm positivity. However, (i) ROS1 rearrangements are rare (1\u20132% of NS-NSCLC), (ii) the specificity of ROS1 IHC is not optimal, and (iii) ROS1 FISH is not widely available, making this algorithm challenging to interpret time-consuming. We evaluated RNA NGS, which was used as reflex testing for ROS1 rearrangements in NS-NSCLC with the aim of replacing ROS1 IHC as a screening method. ROS1 IHC and RNA NGS were prospectively performed in 810 NS-NSCLC. Positive results were analyzed by ROS1 FISH. ROS1 IHC was positive in 36\/810 (4.4%) cases that showed variable staining intensity while NGS detected ROS1 rearrangements in 16\/810 (1.9%) cases. ROS1 FISH was positive in 15\/810 (1.8%) of ROS1 IHC positive cases and in all positive ROS1 NGS cases. Obtaining both ROS1 IHC and ROS1 FISH reports took an average of 6 days, while obtaining ROS1 IHC and RNA NGS reports took an average of 3 days. These results showed that systematic screening for the ROS1 status using IHC must be replaced by NGS reflex testing.<\/jats:p>","DOI":"10.3390\/jpm13050810","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T03:32:27Z","timestamp":1683689547000},"page":"810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-1627","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Hofman","sequence":"first","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-5636","authenticated-orcid":false,"given":"Samantha","family":"Goffinet","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-6197","authenticated-orcid":false,"given":"Christophe","family":"Bontoux","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-6713","authenticated-orcid":false,"given":"Elodie","family":"Long-Mira","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lassalle","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-1236","authenticated-orcid":false,"given":"Marius","family":"Ili\u00e9","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-9353","authenticated-orcid":false,"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University C\u00f4te d\u2019Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France"},{"name":"Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 06000 Nice, France"},{"name":"Team 4, IRCAN Inserm U1081, CNRS 7284, Universit\u00e9 C\u00f4te d\u2019Azur, 06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., and Roviello, G. (2020). Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113293"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: A review with recommendations","volume":"469","author":"Bubendorf","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2021.08.003","article-title":"Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer","volume":"160","author":"Cheung","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/arpa.2019-0085-OA","article-title":"Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization","volume":"144","author":"Huang","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_8","first-page":"100100","article-title":"Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations","volume":"2","author":"Huang","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.3390\/curroncol28050284","article-title":"Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System","volume":"28","author":"Makarem","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pathol.2021.07.006","article-title":"ROS1 rearrangements in non-small cell lung cancer: Screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance","volume":"54","author":"Prall","year":"2022","journal-title":"Pathology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/his.13076","article-title":"Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target","volume":"70","author":"Selinger","year":"2017","journal-title":"Histopathology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/modpathol.2013.192","article-title":"Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers","volume":"27","author":"Yoshida","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.21037\/jtd.2018.11.85","article-title":"The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients","volume":"11","author":"Hofman","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00428-022-03344-1","article-title":"Expert opinion on NSCLC small specimen biomarker testing\u2014Part 2: Analysis, reporting, and quality assessment","volume":"481","author":"Kerr","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_16","first-page":"100457","article-title":"Ultra-fast gene fusion assessment for in non-squamous non-small cell lung cancer","volume":"4","author":"Hofman","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ili\u00e9, M., Hofman, V., Bontoux, C., Heeke, S., Lespinet-Fabre, V., Bordone, O., Lassalle, S., Lalv\u00e9e, S., Tanga, V., and Allegra, M. (2022). Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). Cancers, 14.","DOI":"10.3390\/cancers14092258"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2019.07.017","article-title":"Clinical significance of ROS1 5\u2019 deletions in non-small cell lung cancer","volume":"135","author":"Capizzi","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/his.12379","article-title":"ROS1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases","volume":"65","author":"Warth","year":"2014","journal-title":"Histopathology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jtho.2019.07.005","article-title":"Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: The ROSING Study","volume":"14","author":"Conde","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14737159.2021.1919512","article-title":"Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody","volume":"21","author":"Conde","year":"2021","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2019.03.024","article-title":"Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients","volume":"14","author":"Hofman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2020.06.019","article-title":"Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer","volume":"146","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pathol.2021.07.012","article-title":"ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1","volume":"54","author":"Fielder","year":"2022","journal-title":"Pathology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kang, S., Woo, J., and Kim, S. (2022). A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051297"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jmoldx.2020.09.006","article-title":"Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer","volume":"22","author":"Keppens","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_28","first-page":"300","article-title":"Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: A meta-analysis","volume":"4","author":"Zhu","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/PAI.0000000000000973","article-title":"Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization","volume":"30","author":"Wilcock","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/gcc.23022","article-title":"Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications","volume":"61","author":"Kazdal","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1158\/1078-0432.CCR-12-0838","article-title":"Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions","volume":"18","author":"Suehara","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ijc.33447","article-title":"Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases","volume":"148","author":"Huang","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13258-022-01326-w","article-title":"Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients","volume":"45","author":"Li","year":"2023","journal-title":"Genes Genom."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Horgan, D., Curigliano, G., Rie\u00df, O., Hofman, P., B\u00fcttner, R., Conte, P., Cufer, T., Gallagher, W.M., Georges, N., and Kerr, K. (2022). Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. J. Pers. Med., 12.","DOI":"10.3390\/jpm12010072"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rojo, F., Conde, E., Torres, H., Cabez\u00f3n-Guti\u00e9rrez, L., Bautista, D., Ramos, I., Carcedo, D., Arrabal, N., Garc\u00eda, J.F., and Gal\u00e1n, R. (2022). Clinical and economic impact of \u2018ROS1-testing\u2019 strategy compared to a \u2018no-ROS1-testing\u2019 strategy in advanced NSCLC in Spain. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09397-4"},{"key":"ref_37","first-page":"100434","article-title":"Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC","volume":"3","author":"Buglioni","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jmoldx.2022.05.004","article-title":"Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer","volume":"24","author":"Depoilly","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jclinpath-2021-207490","article-title":"Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing","volume":"75","author":"Conde","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hofman, V., Lassalle, S., Bence, C., Long-Mira, E., Nahon-Est\u00e8ve, S., Heeke, S., Lespinet-Fabre, V., Butori, C., Ili\u00e9, M., and Hofman, P. (2018). Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?. Cancers, 10.","DOI":"10.3390\/cancers10030070"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jtho.2018.05.041","article-title":"Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples","volume":"13","author":"Davies","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.022","article-title":"Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer","volume":"166","author":"Beaulande","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pujol, N., Heeke, S., Bontoux, C., Boutros, J., Ili\u00e9, M., Hofman, V., Marquette, C.H., Hofman, P., and Benzaquen, J. (2022). Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101684"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/5\/810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:31:48Z","timestamp":1760124708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/5\/810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jpm13050810"],"URL":"https:\/\/doi.org\/10.3390\/jpm13050810","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}